Zuviphos 50mg - Cyclophosphamide Tablets

Name: Zuviphos 50mg - Cyclophosphamide Tablets
Brand: NEXT GEN BIOTECH
Price: 390.0 INR
Availability: InStock

Price 390.0 INR/ Box

Get a Price/Quote

MOQ : 1 Box

Zuviphos 50mg - Cyclophosphamide Tablets Specification

Dosage Form
Tablets

Salt Composition
Cyclophosphamide Tablets

Indication
Treatment of Lymphoma, Leukemia, Multiple Myeloma, Breast Cancer, and Ovarian Cancer

Origin
India

Enzyme Types
Other

Feature
Other

Ingredients
Other

Application
Other

Ph Level
N/A

Temperature Needed For Fermentation
25 Celsius (oC)

Physical Color/Texture
Other

Fermentation Smell
Normal Smell

Enzymatic Activity
Alkylating Agent

Storage Instructions
Store below 25 C in a cool, dry place. Protect from moisture and direct sunlight.

Shelf Life
24 Months

Zuviphos 50mg - Cyclophosphamide Tablets Trade Information

Minimum Order Quantity
1 Box

FOB Port
Delhi

Payment Terms
Cash in Advance (CID), Cash Advance (CA)

Supply Ability
500 Boxes Per Month

Delivery Time
100 Days

Sample Available
No

Sample Policy
Contact us for information regarding our sample policy

Packaging Details
Box

Main Export Market(s)
Asia

Main Domestic Market
All India

Certifications
N/A

Zuviphos 50mg - Cyclophosphamide Tablets About

Cyclophosphamide, a chemotherapy drug, was first developed in the 1950s by scientists at the pharmaceutical company Boehringer Ingelheim. It was introduced for clinical use in 1959, and since then, it has become an essential treatment for various cancers and autoimmune conditions. Cyclophosphamides approval by regulatory bodies, including the U.S. Food and Drug Administration (FDA), marked a significant breakthrough in cancer treatment. It is now widely used in oncology and rheumatology for its ability to target rapidly dividing cells.

In clinical trials, cyclophosphamide demonstrated its ability to inhibit the growth of various cancer types, including breast cancer, lymphoma, leukaemia, and multiple myeloma. Its effectiveness in autoimmune diseases, such as lupus and rheumatoid arthritis, has also been a major area of research. Ongoing clinical trials continue to explore new indications, dosages, and combination therapies to improve patient outcomes.